dsg2 Antibody (13B11): sc-135815
- dsg2 Antibody (13B11) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against a recombinant protein corresponding to amino acids 37-164 of dsg2 of human origin
- recommended for detection of the EC1 region of dsg2 of human origin by WB and IP
- See dsg2 (AH12.2): sc-80663 for dsg2 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for dsg2 Antibody (13B11) for WB applications. These reagents are now offered in bundles with dsg2 Antibody (13B11) (see ordering information below).
QUICK LINKS
dsg2 Antibody (13B11) is a mouse monoclonal IgG1 antibody that detects desmoglein 2 in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). anti-desmoglein 2 antibody (13B11) plays a crucial role in understanding the function of desmoglein 2, a vital component of desmosomes, which are specialized cell junctions that provide mechanical strength and stability to tissues, particularly in the skin. Desmoglein 2 is essential for maintaining cell adhesion and integrity, and dysfunction is implicated in various skin disorders, including pemphigus, where autoantibodies target desmogleins, leading to blistering and loss of adhesion. Notably, desmoglein 2 is the largest member of the desmoglein family and is expressed in all desmosome-containing tissues, highlighting its importance in cellular architecture and signaling. Proper functioning of desmoglein 2 is critical not only for normal skin physiology but also for preventing pathological conditions associated with compromised cell adhesion, making desmoglein 2 (13B11) monoclonal antibody an invaluable tool for researchers studying skin biology and related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
dsg2 Antibody (13B11) References:
- Arrhythmogenic cardiomyopathy related DSG2 mutations affect desmosomal cadherin binding kinetics. | Dieding, M., et al. 2017. Sci Rep. 7: 13791. PMID: 29062102
- DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer. | Qin, S., et al. 2020. Cancer Cell Int. 20: 206. PMID: 32514251
- Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion. | Lee, K., et al. 2020. Endocr Relat Cancer. 27: 601-614. PMID: 33022637
- Dsg2 Upregulation as a Rescue Mechanism in Pemphigus. | Sigmund, AM., et al. 2020. Front Immunol. 11: 581370. PMID: 33193387
- DSG2 expression is low in colon cancer and correlates with poor survival. | Yang, T., et al. 2021. BMC Gastroenterol. 21: 7. PMID: 33407183
- Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy. | Qiu, Z., et al. 2022. Cells. 11: PMID: 36291052
- Molecular insight into arrhythmogenic cardiomyopathy caused by DSG2 mutations. | Zhang, B., et al. 2023. Biomed Pharmacother. 167: 115448. PMID: 37696084
- Serine/threonine-protein kinase D2-mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression. | Liu, YQ., et al. 2024. J Pathol. 263: 99-112. PMID: 38411280
- Up-regulated DSG2 promotes tumor growth and reduces immune infiltration in cervical cancer. | Zhang, G., et al. 2024. Pathol Res Pract. 262: 155554. PMID: 39226803
- Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant. | Zhang, B., et al. 2024. BMC Med. 22: 361. PMID: 39227800
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
dsg2 Antibody (13B11) | sc-135815 | 200 µg/ml | $322.00 | |||
dsg2 Antibody (13B11): m-IgG Fc BP-HRP Bundle | sc-539886 | 200 µg Ab; 10 µg BP | $361.00 | |||
dsg2 Antibody (13B11): m-IgG1 BP-HRP Bundle | sc-541763 | 200 µg Ab; 20 µg BP | $361.00 |